Xenon Pharmaceuticals Inc. (XENE)
Summary
Xenon Pharmaceuticals Q2 Earnings Call Highlights
10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from the prior-year quarter.
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
Xenon Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 126 | $4,346.56 | $8,089.2 | $3,742.64 | 86.11% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 100 | $4,482 | $6,336 | $1,854 | 41.37% |
| NA Nizar Araji National Bank Of Canada /FI/ | 235 | $10,024.85 | $14,889.6 | $4,864.75 | 48.53% |
| BG Bart Gancher Intech Investment Management LLC | 21,758 | $796,605.24 | $1.38M | $581,981.64 | 73.06% |
 John H. Burbank III Passport Capital LLC | 370,208 | $13.53M | $23.08M | $9.55M | 70.63% |
Xenon Pharmaceuticals Inc. (XENE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Xenon Pharmaceuticals Inc. ever had a stock split?
Xenon Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ian C. Mortimer CEO | NASDAQ (NMS) Exchange | 98420N105 CUSIP |
| CA Country | 364 Employees | - Last Dividend | - Last Split | 5 Nov 2014 IPO Date |
Overview
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, founded in 1996. This company is primarily focused on the development of innovative therapeutics for neurological disorders. Through its extensive research and clinical trials, Xenon Pharmaceuticals aims to address some of the most challenging conditions affecting the nervous system, with a particular emphasis on various forms of epilepsy and other neurological disorders. It operates in Canada and collaborates with strategic partners such as Neurocrine Biosciences, Inc. and Flexion Therapeutics, Inc., to expand its reach and capabilities in developing effective treatments for these complex conditions.
Products and Services
- XEN496
A Kv7 potassium channel opener currently in Phase III clinical trials specifically targeted for KCNQ2 developmental and epilepsy encephalopathy. This product represents a potential breakthrough in treating this rare and severe form of epilepsy that begins in the neonatal period.
- XEN1101
Another Kv7 potassium channel opener, but it is in Phase II clinical trials. XEN1101 is being explored for its potential use in treating epilepsy and other neurological disorders, indicating its broad therapeutic application across a range of conditions that affect the central nervous system.
- NBI-921352
This compound is a selective Nav1.6 sodium channel inhibitor currently undergoing Phase II clinical trials. It is being tested for its efficacy in treating SCN8A developmental and epileptic encephalopathy and holds potential for other indications, such as adult focal epilepsy. NBI-921352's specificity for Nav1.6 channels makes it a promising candidate for addressing disorders arising from this channel's dysfunction.
- XEN007
A central nervous system-acting calcium channel modulator in Phase II clinical trials. XEN007's mechanism of action offers a unique approach to modulating brain activity, making it a candidate for treating a variety of neurological conditions where calcium channels play a key role in disease pathology.
- Collaborations for Epilepsy Treatments and Post-operative Pain
Xenon Pharmaceuticals has entered into license and collaboration agreements with Neurocrine Biosciences, Inc., focusing on developing innovative treatments for epilepsy. Additionally, in collaboration with Flexion Therapeutics, Inc., the company is developing PCRX301 (XEN402), a Nav1.7 inhibitor, for managing post-operative pain. These partnerships underscore its commitment to expanding its portfolio and enhancing treatment options for patients with neurological disorders.
